Hallgeir Rui

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6596173/publications.pdf

Version: 2024-02-01

63 papers	2,511 citations	218592 26 h-index	206029 48 g-index
67 all docs	67 docs citations	67 times ranked	3616 citing authors

#	Article	IF	Citations
1	Cytotoxic CD8-positive T-lymphocyte infiltration in the lungs as a histological pattern of SARS-CoV-2 pneumonitis. Pathology, 2022, 54, 404-408.	0.3	4
2	Spatial Metrics of Interaction between CD163-Positive Macrophages and Cancer Cells and Progression-Free Survival in Chemo-Treated Breast Cancer. Cancers, 2022, 14, 308.	1.7	8
3	Abstract OT2-16-01: The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2- metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors. Cancer Research, 2022, 82, OT2-16-01-OT2-16-01.	0.4	0
4	Abstract P4-02-03: HER1-4 protein up-regulation following short-term neoadjuvant endocrine therapy in patients with hormone receptor-positive HER2-negative breast cancer. Cancer Research, 2022, 82, P4-02-03-P4-02-03.	0.4	0
5	A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study.. Journal of Clinical Oncology, 2022, 40, TPS220-TPS220.	0.8	0
6	Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2022, 82, P5-17-08-P5-17-08.	0.4	2
7	Quantification of spatial tumor heterogeneity in immunohistochemistry staining images. Bioinformatics, 2021, 37, 1452-1460.	1.8	8
8	Prolonged Time from Diagnosis to Breast-Conserving Surgery is Associated with Upstaging in Hormone Receptor-Positive Invasive Ductal Breast Carcinoma. Annals of Surgical Oncology, 2021, 28, 5895-5905.	0.7	7
9	Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. Endocrinology, 2021, 162, .	1.4	8
10	ASO Author Reflections: Does Prompt Breast-Conserving Surgery Matter?. Annals of Surgical Oncology, 2021, 28, 5906-5906.	0.7	0
11	Regulation of intercellular biomolecule transferâ€“driven tumor angiogenesis and responses to anticancer therapies. Journal of Clinical Investigation, 2021, 131, .	3.9	11
12	Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells. Nature Communications, 2021, 12, 3742.	5.8	24
13	Theory, methods, and operational results of the Young Womenâ€™s Health History Study: a study of young-onset breast cancer incidence in Black and White women. Cancer Causes and Control, 2021, 32, 1129-1148.	0.8	4
14	Diffuse interstitial pneumonia-like/macrophage activation syndrome-like changes in patients with COVID-19 correlate with length of illness. Annals of Diagnostic Pathology, 2021, 53, 151744.	0.6	2
15	Pneumocytes are distinguished by highly elevated expression of the ER stress biomarker GRP78, a co-receptor for SARS-CoV-2, in COVID-19 autopsies. Cell Stress and Chaperones, 2021, 26, 859-868.	1.2	20
16	Oncostatin M Receptorâ€“Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. Cancer Research, 2021, 81, 5336-5352.	0.4	27
17	NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers. Science Advances, 2021, 7, eabc8145.	4.7	10
18	RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site. Cell Reports, 2021, 37, 109934.	2.9	34

#	Article	IF	Citations
19	Individualized multi-omic pathway deviation scores using multiple factor analysis. Biostatistics, 2020, , .	0.9	3
20	The membrane-associated form of cyclin D1 enhances cellular invasion. Oncogenesis, 2020, 9, 83.	2.1	16
21	Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis. Oncogene, 2020, 39, 6129-6137.	2.6	16
22	Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. Cancer Biology and Therapy, 2020, 21, 629-636.	1.5	7
23	Functional Blockade of E-Selectin in Tumor-Associated Vessels Enhances Anti-Tumor Effect of Doxorubicin in Breast Cancer. Cancers, 2020, 12, 725.	1.7	6
24	Acquired Immunity Is Not Essential for Radiation-Induced Heart Dysfunction but Exerts a Complex Impact on Injury. Cancers, 2020, 12, 983.	1.7	6
25	Exploring drivers of gene expression in the Cancer Genome Atlas. Bioinformatics, 2019, 35, 62-68.	1.8	21
26	The p52 isoform of SHC1 is a key driver of breast cancer initiation. Breast Cancer Research, 2019, 21, 74.	2.2	29
27	Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome. Breast Cancer Research and Treatment, 2019, 177, 77-91.	1.1	3
28	Mapping genetic modifiers of radiation-induced cardiotoxicity to rat chromosome 3. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H1267-H1280.	1.5	30
29	Identification of a Rat Mammary Tumor Risk Locus That Is Syntenic with the Commonly Amplified 8q12.1 and 8q22.1 Regions in Human Breast Cancer Patients. G3: Genes, Genomes, Genetics, 2019, 9, 1739-1743.	0.8	5
30	An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell, 2019, 35, 33-45.e6.	7.7	125
31	Mapping Mammary Tumor Traits in the Rat. Methods in Molecular Biology, 2019, 2018, 249-267.	0.4	3
32	Adverse Effects of Chemotherapy on Human Microvascular Function. FASEB Journal, 2019, 33, lb453.	0.2	2
33	CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. Cancer Research, 2018, 78, 1657-1671.	0.4	97
34	Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9298-E9307.	3.3	91
35	Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling. Clinical Cancer Research, 2018, 24, 6355-6366.	3.2	16
36	New Insights into the Role of SmgGDS as a Major Integrator of Signaling by Ras and Rho Family Members in Cancer. FASEB Journal, 2018, 32, 661.8.	0.2	0

#	Article	IF	Citations
37	Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell, 2017, 31, 194-207.	7.7	179
38	Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a U.S. Military Medical Center and Matched Patients From the U.S. General Population. Military Medicine, 2017, 182, e1851-e1858.	0.4	8
39	Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget, 2017, 8, 81754-81775.	0.8	32
40	The effect of soluble E-selectin on tumor progression and metastasis. BMC Cancer, 2016, 16, 331.	1.1	39
41	E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases. Molecular Therapy - Nucleic Acids, 2016, 5, e399.	2.3	26
42	Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation. Journal of Investigative Dermatology, 2016, 136, 1990-2002.	0.3	25
43	Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms. Modern Pathology, 2016, 29, 1143-1154.	2.9	25
44	Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Reports, 2016, 15, 171-180.	2.9	83
45	Safety evaluation of intravenously administered mono-thioated aptamer against E-selectin in mice. Toxicology and Applied Pharmacology, 2015, 287, 86-92.	1.3	13
46	Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Molecular Cancer Therapeutics, 2015, 14, 1777-1793.	1.9	42
47	Blocking the Adhesion Cascade at the Premetastatic Niche for Prevention of Breast Cancer Metastasis. Molecular Therapy, 2015, 23, 1044-1054.	3.7	46
48	Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. American Journal of Pathology, 2015, 185, 2505-2522.	1.9	54
49	Triggering ubiquitination of <scp>IFNAR</scp> 1 protects tissues from inflammatory injury. EMBO Molecular Medicine, 2014, 6, 384-397.	3.3	52
50	The Paracrine Hormone for the GUCY2C Tumor Suppressor, Guanylin, Is Universally Lost in Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2328-2337.	1.1	49
51	Global profiling of prolactin-modulated transcripts in breast cancer in vivo. Molecular Cancer, 2013, 12, 59.	7.9	26
52	Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer. Cancer Research, 2013, 73, 1821-1830.	0.4	66
53	Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Research, 2012, 14, R130.	2.2	63
54	Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Research, 2011, 13, R11.	2.2	53

#	Article	IF	Citations
55	Loss of Nuclear Localized and Tyrosine Phosphorylated Stat5 in Breast Cancer Predicts Poor Clinical Outcome and Increased Risk of Antiestrogen Therapy Failure. Journal of Clinical Oncology, 2011, 29, 2448-2458.	0.8	97
56	Prolactin Inhibits BCL6 Expression in Breast Cancer through a Stat5a-Dependent Mechanism. Cancer Research, 2010, 70, 1711-1721.	0.4	68
57	Insensitivity of Human Prolactin Receptors to Nonhuman Prolactins: Relevance for Experimental Modeling of Prolactin Receptor-Expressing Human Cells. Endocrinology, 2009, 150, 1782-1790.	1.4	40
58	Coactivation of Janus Tyrosine Kinase (Jak)1 Positively Modulates Prolactin-Jak2 Signaling in Breast Cancer: Recruitment of ERK and Signal Transducer and Activator of Transcription (Stat)3 and Enhancement of Akt and Stat5a/b Pathways. Molecular Endocrinology, 2007, 21, 2218-2232.	3.7	58
59	Ultrahigh density microarrays of solid samples. Nature Methods, 2005, 2, 511-513.	9.0	42
60	Signal Transducer and Activator of Transcription-5 Activation and Breast Cancer Prognosis. Journal of Clinical Oncology, 2004, 22, 2053-2060.	0.8	217
61	Generation of a conditional knockout allele for theJanus kinase 2 (Jak2) gene in mice. Genesis, 2004, 40, 52-57.	0.8	244
62	Role of serine phosphorylation of Stat5a in prolactin-stimulated Î²-casein gene expression. Molecular and Cellular Endocrinology, 2001, 183, 151-163.	1.6	80
63	Differential Control of the Phosphorylation State of Proline-juxtaposed Serine Residues Ser725 of Stat5a and Ser730 of Stat5b in Prolactin-sensitive Cells. Journal of Biological Chemistry, 1998, 273, 30218-30224.	1.6	132